Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

ORIGINAL ARTICLE

Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis

Online download statistics by month:

Online download statistics by month: March 2019 to March 2023

	Abstract	Full	Pdf
Mar 2019	4	0	0
Apr 2019	14	0	0
May 2019	18	0	1
Jun 2019	16	0	0
Jul 2019	28	0	2
Aug 2019	32	0	1
Sep 2019	14	0	0
Oct 2019	18	0	0
Nov 2019	2	0	0
Dec 2019	10	0	0
Jan 2020	16	0	0
Feb 2020	10	0	1
Mar 2020	6	0	2
Apr 2020	6	0	0
May 2020	16	0	0
Jun 2020	10	0	1
Jul 2020	16	0	0
Aug 2020	4	0	2
Sep 2020	20	0	2
Oct 2020	14	0	1
Nov 2020	12	0	0
Dec 2020	14	0	3
Jan 2021	18	0	1
Feb 2021	18	0	1
Mar 2021	20	0	2
Apr 2021	2	0	2
May 2021	2	0	0
Jul 2021	1	0	1
Aug 2021	0	0	1
Oct 2021	30	0	0
Nov 2021	8	0	1
Dec 2021	14	0	0
Jan 2022	19	0	2
Feb 2022	8	0	0
Mar 2022	23	0	0
Apr 2022	8	0	0
May 2022	41	0	0
Jun 2022	61	0	0
Jul 2022	16	0	0
Aug 2022	50	0	0
Sep 2022	36	0	0
Oct 2022	60	0	0
Nov 2022	12	0	0
Dec 2022	16	0	0
Jan 2023	40	0	0
Feb 2023	72	0	0
Mar 2023	6	0	0
Total	881	0	27